According to current national and international guidelines, individuals with type 2 diabetes who also have HF, chronic renal disease, cardiovascular illness, or cardiovascular risk factors should take SGLT2 inhibitors (4). The gene discussed is SLC5A2; the disease is hydrops fetalis.